SOURCE-LINKED STUDY SUMMARY
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.
Full paper summarizedQuality not appraised
- What was studied
- This phase 2 trial tested whether semaglutide increased bone formation in adults already at increased fracture risk.
- Who / model studied
- Sixty-four adults—55 postmenopausal women and nine men—had low bone density and/or a recent low-energy fracture.
- Studied dose & schedule
- Participants received semaglutide 1.0 mg or placebo subcutaneously once weekly for 52 weeks.
- What the study found
- Semaglutide did not improve PINP. CTX was 166.4 ng/L higher; lumbar-spine and total-hip BMD were lower, alongside 6.8 kg greater weight loss. Adverse events occurred in 97% versus 56%.
- Limitations & context
- The small, two-site, ethnically limited study could not separate direct drug effects from skeletal adaptation to weight loss or assess fracture outcomes.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.eclinm.2024.102624